India's Aurobindo Pharma falls on flat FY26 margins forecast

ICICI Securities

28/05/2025 06:53

** Shares of Aurobindo Pharma ARBN.NS fall 2.46% to 1,162.5 rupees

** Co posts marginal decline in Q4 profit, forecasts flat margins for FY26

** Co expects lower sales of generic cancer drug Revlimid due to increased competition as patent expires next year

** Flags delay in ramp-up of Andhra Pradesh plant

** At least 10 analysts cut PT; 3 downgrade stock - per data compiled by LSEG

** BofA says FY26 margin forecast below its estimate

** HSBC cuts FY26 EPS estimate by 4.5% due to lower Revlimid sales

** ICICI Securities cuts FY26 and FY27 core profit estimates by ~12% and ~8%, respectively, due to lower sales from subsidiary Eugia Pharma Specialties

 (Reporting by Ananta Agarwal in Bengaluru)

 ((Ananta.Agarwal@thomsonreuters.com))